BORTECAD 2MG INJECTION

Bortecad 2mg Injection is a prescription anticancer product containing bortezomib, a potent proteasome inhibitor widely used in the treatment of multiple myeloma and mantle cell lymphoma. This injectable therapy helps control cancer progression by targeting proteasomes, essential structures for cancer cell survival.

The active ingredient, bortezomib, works by blocking proteasomes inside cancer cells, causing the accumulation of damaged proteins and triggering cell death. By disrupting these processes, Bortecad slows disease progression and enhances the effectiveness of combination chemotherapy regimens under oncologist supervision.

Bortecad 2 mg injection is administered intravenously or subcutaneously under strict hospital or clinical supervision. This prescription-only product ensures consistent therapeutic effectiveness, patient safety, and reliable outcomes in the management of hematological malignancies.

Product Features

• Targeted anticancer chemotherapy injection
• Contains Bortezomib 2 mg
• Proteasome inhibitor for blood cancers
• Used in multiple myeloma & mantle cell lymphoma
• Sterile injectable formulation
• Administered intravenously or subcutaneously (as prescribed)
• Manufactured under GMP-compliant quality standards
• Prescription-required oncology medicine

How It Helps

• Blocks proteasomes to induce cancer cell death
• Helps slow disease progression in multiple myeloma and mantle cell lymphoma
• Supports effective chemotherapy in blood cancers
• Provides targeted anticancer therapy under an oncologist’s supervision